Indeed, further studies that aim to assess the impact of different mAbs on specific asthma phenotypes according to the levels of IgE, IL-4, IL-5, and IL-13 may further optimize the efficacy of the current mAbs for the treatment of severe asthma. This evidence concerns the gene IL5 and asthma.